An independent GLP-1 safety database. Real data from clinical trials, patient experiences, and regulatory reports — free, with every source cited.
1,334
Data points
15
Effects tracked
9
Drugs covered
16
Data sources
See your personalised risk profile for 15 side effects
Try itPredict your weight loss journey based on STEP trial data
Try itAssess your risk of muscle loss and get evidence-based recommendations
Try itUnderstand what happens when you stop — and how to prepare
Try itOur Companies House audit: 98 brand-new shell companies, no credible GLP-1 supplier, and documented harm.
Read moreIndia's patent expiry opens the door for dozens of affordable generic versions.
Read moreRegistered generics make weight management accessible to millions.
Read more
011,100+ structured data points across 15 side effects and 9 medications — updated daily, sources cited.
02The free predictor estimates your side-effect risks and weight trajectory from your profile.
03Clinical trials side by side with real-world reports, plus weekly market and pricing analysis by country.
04Missing a side effect, drug, or data source? Your suggestions steer what we collect next.
Almost everything written about GLP-1 online comes from someone selling you something — the manufacturer, a clinic, or the grey market. We don't sell medication. We publish the data.
We don't prescribe, don't dispense, and earn nothing from your treatment — so our numbers have nothing to sell. Every data point carries its source: clinical trials, FDA FAERS, regulators, and patient reports. Methodology published in full.
Read the methodologyAn independent, fully cited GLP-1 safety and efficacy database — drawn from clinical trials, FDA FAERS, regulatory reports, and patient experiences. Personalised forecasts for weight loss, side effects, and muscle preservation, shared between you and your doctor.
See your forecastLive tracking of GLP-1 supply, demand, and international trade across major global markets — patent expiries, licensed generic launches, cross-market pricing, and cold-chain integrity. So you know your medicine is legitimate and properly handled.
Explore the marketGeneric semaglutide is now launching in India, Canada, and Brazil. Is it the same as Ozempic? Here's what equivalence actually means — and what to look for.
ReadOzempic costs €300+ per month in some countries and €14 in others. Here's the patent economics behind the price — and why 2026 is changing everything.
ReadConsidering semaglutide for weight management? Here's what to expect in week 1, month 1, and beyond — from dose titration to side effects to lifestyle pairings.
ReadAccess the GLP-1 Safety Database via our public API. Free for citations, subscription for bulk access.
curl magistra.health/api/data?q=overview{
"totalDataPoints": 1,334,
"effectsTracked": 15,
"drugsCovered": 9,
"sources": ["pubmed", "fda_faers", "reddit", ...]
}Magistra is a data source, not a clinic. Everything below is available right now, free and without an account.
Side-effect risk, weight trajectory, muscle loss, and discontinuation outlook, fitted to your characteristics.
1,334 data points, each carrying its source, with clinical and real-world rates kept separate.
Free public API, citable dataset, and published methodology for researchers, analysts, and journalists.
The database grows daily. Leave your email and we'll write when a major dataset release or new finding lands. No sales, no medication.
See your personal GLP-1 side-effect risk